Skip to main content
SpringerLink
Log in

Surgical and Medical Options in the Management of Renal Cell Carcinoma

  • Chapter
  • First Online:
Onconephrology

  • 961 Accesses

Abstract

Given the increasing detection rate of renal mass with the widespread utilization of cross-sectional imaging and the rising incidence rate of renal cell carcinoma (RCC), it is imperative that the nephrologist understands the behavior of this cancer, the treatment options available, and the impact of treatment on renal functional outcomes. Here, we present a review of various histologic subtypes of RCC, up-to-date surgical and medical treatment options, and their respective outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

AS:

Active Surveillance

AUA:

American Urological Association

BHD:

Birt–Hogg–Dube

CKD:

Chronic kidney disease

CR:

Complete response

CT:

Computed tomography

DFS:

Disease-free survival

EORTC:

European Organization for Research and Treatment of Cancer

ESKD:

End-stage kidney disease

FGFR:

Fibroblast growth factor receptor

GFR:

Glomerular filtration rate

HLRCC:

Hereditary Leiomyomatosis Renal Cell Cancer

HIF:

Hypoxia inducible factor

IV:

Intravenous

KPS:

Karnofsky performance score

MRI:

Magnetic resonance imaging

MPA:

Medroxyprogesterone

MSKCC:

Memorial Sloan Kettering Cancer Center

mTOR:

Mammalian target of rapamycin

NCCN:

National Comprehensive Cancer Network

NSS:

Nephron sparing surgery

OS:

Overall survival

PDGF:

Platelet-derived growth factor

PDGFR:

Platelet-derived growth factor receptor

PFS:

Progression-free survival

PN:

Partial nephrectomy

RCC:

Renal cell cancer

RFA:

Radiofrequency ablation

RN:

Radical Nephrectomy

TGF:

Transforming growth factor

TKI:

Tyrosine kinase inhibitors

VEGF:

Vascular endothelial growth factor

VEGFR:

Vascular endothelial growth factor receptor

VHL:

von Hippel–Lindau

References

  1. Cancer of the Kidney and Renal Pelvis – SEER Stat Fact Sheets [Internet]. seer.cancer.gov. [cited 2014 ]. http://seer.cancer.gov/statfacts/html/kidrp.html.

  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.

    Article  PubMed  Google Scholar 

  3. Cote ML, Colt JS, Schwartz KL, Wacholder S, Ruterbusch JJ, Davis F, et al. Cigarette smoking and renal cell carcinoma risk among black and white Americans: effect modification by hypertension and obesity. Cancer Epidemiol Biomarkers Prev. 2012;21(5):770–9.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Kroeger N, Klatte T, Birkhäuser FD, Rampersaud EN, Seligson DB, Zomorodian N, et al. Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival. Cancer. 2012;118(7):1795–802.

    Article  PubMed  Google Scholar 

  5. Sunela KL, Kataja MJ, Kellokumpu-Lehtinen P-LI. Influence of body mass index and smoking on the long-term survival of patients with renal cell cancer. Clin Genitourin Cancer. 2013;11(4):458–64.

    Article  PubMed  Google Scholar 

  6. Ljungberg B, Campbell SC, Choi HY, Cho HY, Jacqmin D, Lee JE, et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60(4):615–21.

    Article  PubMed  Google Scholar 

  7. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335(7630):1134.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Schrader AJ, Rustemeier J, Rustemeier JC, Timmesfeld N, Varga Z, Hegele A, et al. Overweight is associated with improved cancer-specific survival in patients with organ-confined renal cell carcinoma. J Cancer Res Clin Oncol. 2009;135(12):1693–9.

    Article  PubMed  Google Scholar 

  9. Colt JS, Schwartz K, Graubard BI, Davis F, Ruterbusch J, DiGaetano R, et al. Hypertension and risk of renal cell carcinoma among white and black Americans. Epidemiology. 2011;22(6):797–804.

    PubMed Central  PubMed  Google Scholar 

  10. Fryzek JP, Poulsen AH, Johnsen SP, McLaughlin JK, Sørensen HT, Friis S. A cohort study of antihypertensive treatments and risk of renal cell cancer. Br J Cancer. 2005;92(7):1302–6.

    Google Scholar 

  11. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol. 2006;176(6 Pt 1):2353–8.

    Article  PubMed  Google Scholar 

  12. Gigante M, Neuzillet Y, Patard J-J, Tillou X, Thuret R, Branchereau J, et al. Renal cell carcinoma (RCC) arising in native kidneys of dialyzed and transplant patients: are they different entities? BJU Int. 2012 ;110(11 Pt B):E570–3.

    Article  PubMed  Google Scholar 

  13. Neuzillet Y, Tillou X, Mathieu R, Long J-A, Gigante M, Paparel P, et al. Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol. 2011;60(2):366–73.

    Article  PubMed  Google Scholar 

  14. Sassa N, Hattori R, Tsuzuki T, Watarai Y, Fukatsu A, Katsuno S, et al. Renal cell carcinomas in haemodialysis patients: does haemodialysis duration influence pathological cell types and prognosis? Nephrol Dial Transplant. 2011;26(5):1677–82.

    Article  PubMed  Google Scholar 

  15. Nouh MAAM, Kuroda N, Yamashita M, Hayashida Y, Yano T, Minakuchi J, et al. Renal cell carcinoma in patients with end-stage renal disease: relationship between histological type and duration of dialysis. BJU Int. 2010;105(5):620–7.

    Article  PubMed  Google Scholar 

  16. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol. 2003;170(6 Pt 1):2163–72.

    Article  CAS  PubMed  Google Scholar 

  17. Linehan WM, Lerman MI, Zbar B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA. 1995;273(7):564–70.

    Article  CAS  PubMed  Google Scholar 

  18. Walther MM, Lubensky IA, Venzon D, Zbar B, Linehan WM. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J Urol. 1995;154(6):2010–4; (discussion2014–5).

    Article  CAS  PubMed  Google Scholar 

  19. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7(1):85–90.

    Article  CAS  PubMed  Google Scholar 

  20. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A. 1994;91(21):9700–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Linehan WM, Vasselli J, Srinivasan R, Walther MM, Merino M, Choyke P, et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res. 2004;10(18 Pt 2):6282S–9S.

    Article  CAS  PubMed  Google Scholar 

  22. Rosner I, Bratslavsky G, Pinto PA, Linehan WM. The clinical implications of the genetics of renal cell carcinoma. Urol Oncol. 2009;27(2):131–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Hughson MD, Meloni A, Dougherty S, Silva FG, Sandberg AA. Analysis of 3p allelic loss in papillary and nonpapillary renal cell carcinomas. Correlation with tumor karyotypes. Cancer Genet Cytogenet. 1996;87(2):133–9.

    Article  CAS  PubMed  Google Scholar 

  24. Corless CL, Aburatani H, Fletcher JA, Housman DE, Amin MB, Weinberg DS. Papillary renal cell carcinoma: quantitation of chromosomes 7 and 17 by FISH, analysis of chromosome 3p for LOH, and DNA ploidy. Diagn Mol Pathol. 1996;5(1):53–64.

    Article  CAS  PubMed  Google Scholar 

  25. Grubb RL, Franks ME, Toro J, Middelton L, Choyke L, Fowler S, et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol. 2007;177(6):2074–9; (discussion2079–80).

    Article  CAS  PubMed  Google Scholar 

  26. Menko FH, van Steensel MAM, Giraud S, Friis-Hansen L, Richard S, Ungari S, et al. Birt-Hogg-Dubé syndrome: diagnosis and management. Lancet Oncol. 2009;10(12):1199–206.

    Article  CAS  PubMed  Google Scholar 

  27. Lee WK, Byun S-S, Kim HH, Rha KH, Hwang T-K, Sung GT, et al. Characteristics and prognosis of chromophobe non-metastatic renal cell carcinoma: a multicenter study. Int J Urol. 2010;17(11):898–904.

    Article  PubMed  Google Scholar 

  28. Przybycin CG, Cronin AM, Darvishian F, Gopalan A, Al-Ahmadie HA, Fine SW, et al. Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution. Am J Surg Pathol. 2011;35(7):962–70.

    Article  PubMed  Google Scholar 

  29. Prince MR, Zhang H, Morris M, MacGregor JL, Grossman ME, Silberzweig J, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology. 2008;248(3):807–16.

    Article  PubMed  Google Scholar 

  30. Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment-report of 33 cases. Radiology. 2009;250(2):371–7.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Mühlfeld AS, Lange C, Kroll G, Floege J, Krombach GA, Kuhl C, et al. Pilot study of noncontrast-enhanced MRI vs. ultrasound in renal transplant recipients with acquired cystic kidney disease: a prospective intra-individual comparison. Clin Transplant. 2013;27(6):E694–701.

    Article  PubMed  Google Scholar 

  32. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, et al. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw. 2009;7(6):618–30.

    CAS  PubMed  Google Scholar 

  33. Halverson SJ, Kunju LP, Bhalla R, Gadzinski AJ, Alderman M, Miller DC, et al. Accuracy of determining small renal mass management with risk stratified biopsies: confirmation by final pathology. J Urol. 2013;189(2):441–6.

    Article  PubMed  Google Scholar 

  34. Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH, et al. Follow-up for clinically localized renal neoplasms: AUA guideline. J Urol. 2013;190(2):407–16.

    Article  PubMed  Google Scholar 

  35. Mason RJ, Abdolell M, Trottier G, Pringle C, Lawen JG, Bell DG, et al. Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. Eur Urol. 2011;59(5):863–7.

    Article  PubMed  Google Scholar 

  36. George AK, herati AS, Rais-Bahrami S, waingankar N, Kavoussi LR. Laparoscopic partial nephrectomy for hilar tumors: oncologic and renal functional outcomes. Urology. 2014;83(1):111–5.

    Article  PubMed  Google Scholar 

  37. van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011;59(4):543–52.

    Article  PubMed  Google Scholar 

  38. Tan H-J, Norton EC, Ye Z, Hafez KS, Gore JL, Miller DC. Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. JAMA. 2012;307(15):1629–35.

    Article  CAS  PubMed  Google Scholar 

  39. Salami SS, George AK, Rais-Bahrami S. Outcomes of minimally invasive urologic surgery in the elderly patient population. Curr Transl Geriatr and Exp Gerontol Rep. Current Science Inc. 2013;2(2):84–90.

    Google Scholar 

  40. Gill IS, Patil MB, Abreu AL de C, Ng C, Cai J, Berger A, et al. Zero ischemia anatomical partial nephrectomy: a novel approach. J Urol. 2012;187(3):807–14.

    Article  PubMed  Google Scholar 

  41. Abreu ALC, Gill IS, Desai MM. Zero-ischaemia robotic partial nephrectomy (RPN) for hilar tumours. BJU Int. 2011;108(6 Pt 2):948–54.

    Article  PubMed  Google Scholar 

  42. George AK, herati AS, Srinivasan AK, Rais-Bahrami S, waingankar N, Sadek MA, et al. Perioperative outcomes of off-clamp vs complete hilar control laparoscopic partial nephrectomy. BJU Int. 2013;111(4 Pt B):E235–41.

    Article  PubMed  Google Scholar 

  43. Salami SS, George AK, Rais-Bahrami S, Okhunov Z, waingankar N, Kavoussi LR. Off-clamp laparoscopic partial nephrectomy for hilar tumors: oncologic and renal functional outcomes. J Endourol. 2014;28(2):191–5.

    Article  PubMed  Google Scholar 

  44. Scosyrev E, Messing EM, Sylvester R, Campbell S, Van Poppel H. Renal function after nephron-sparing surgery versus radical nephrectomy: results from eortc randomized trial 30904. Eur Urol. 2014;65(2):372–7.

    Article  PubMed  Google Scholar 

  45. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.

    Article  CAS  PubMed  Google Scholar 

  46. Baust J, Gage AA, Ma H, Zhang CM. Minimally invasive cryosurgery-technological advances. Cryobiology. 1997;34(4):373–84.

    Article  CAS  PubMed  Google Scholar 

  47. Gage AA, Baust J. Mechanisms of tissue injury in cryosurgery. Cryobiology. 1998;37(3):171–86.

    Article  CAS  PubMed  Google Scholar 

  48. Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. AJR Am J Roentgenol. 2000;174(2):323–31.

    Article  CAS  PubMed  Google Scholar 

  49. Lui K-W, Gervais DA, Arellano RA, Mueller PR. Radiofrequency ablation of renal cell carcinoma. Clin Radiol. 2003;58(12):905–13.

    Article  PubMed  Google Scholar 

  50. Dib El R, Touma NJ, Kapoor A. Cryoablation vs radiofrequency ablation for the treatment of renal cell carcinoma: a meta-analysis of case series studies. BJU Int. 2012;110(4):510–6.

    Article  Google Scholar 

  51. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530–40.

    CAS  PubMed  Google Scholar 

  52. Mickisch GH, Garin A, Van Poppel H, de Prijck L, Sylvester R. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. The Lancet. 2001;358(9286):966–70.

    Article  CAS  Google Scholar 

  53. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–9.

    Article  CAS  PubMed  Google Scholar 

  54. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171(3):1071–6.

    Article  PubMed  Google Scholar 

  55. Rini BI. Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol. 2009;27(19):3225–34.

    Article  CAS  PubMed  Google Scholar 

  56. Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med. 1998;338(18):1265–71.

    Article  CAS  PubMed  Google Scholar 

  57. Wong ASA, Chong K-TK, Heng C-TC, Consigliere DTD, Esuvaranathan KK, Toh K-LK, et al. Debulking nephrectomy followed by a “watch and wait” approach in metastatic renal cell carcinoma. Urol Oncol. 2009;27(2):149–54.

    Article  PubMed  Google Scholar 

  58. Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23(4):832–41.

    Article  PubMed  Google Scholar 

  59. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–9.

    Article  CAS  PubMed  Google Scholar 

  60. Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int. 2011;108(10):1556–63.

    Article  CAS  PubMed  Google Scholar 

  61. Heng DYC, Xie W, Bjarnason GA, Vaishampayan U, Tan M-H, Knox J, et al. Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer. 2011;117(12):2637–42.

    Article  PubMed  Google Scholar 

  62. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. The Lancet. 1999;353(9146):14–7.

    Article  Google Scholar 

  63. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425.

    Google Scholar 

  64. Klapper JAJ, Downey SGS, Smith FOF, Yang JCJ, Hughes MSM, Kammula USU, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008;113(2):293–301.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  65. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34.

    Article  CAS  PubMed  Google Scholar 

  66. Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, et al. Randomized phase ii trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(8):1280–9.

    Article  CAS  PubMed  Google Scholar 

  67. Perry MC, Doll DC, Freter CE. Perry’s The Chemotherapy source book. Philadelphia: Lippincott Williams & Wilkins. 2012. (1 p).

    Google Scholar 

  68. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.

    Article  CAS  PubMed  Google Scholar 

  69. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–90.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  70. Sternberg CNC, Davis IDI, Mardiak JJ, Szczylik CC, Lee EE, Wagstaff JJ, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8.

    Article  CAS  PubMed  Google Scholar 

  71. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722–31.

    Article  CAS  PubMed  Google Scholar 

  72. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. The Lancet. 2011;378(9807):1931–9.

    Article  CAS  Google Scholar 

  73. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81.

    Article  CAS  PubMed  Google Scholar 

  74. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. The Lancet. 2008;372(9637):449–56.

    Article  CAS  Google Scholar 

  75. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou S-S, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26(33):5422–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  76. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28(13):2137–43.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  77. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427–34.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  78. Oudard SS, Banu EE, Vieillefond AA, Fournier LL, Priou FF, Medioni JJ, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d’Etudes des Tumeurs Uro-Génitales) study. J Urol. 2007;177(5):1698–702.

    Article  CAS  PubMed  Google Scholar 

  79. Nanus DMD, Garino AA, Milowsky MIM, Larkin MM, Dutcher JPJ. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer. 2004;101(7):1545–51.

    Article  CAS  PubMed  Google Scholar 

  80. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10(8):757–63.

    Article  CAS  PubMed  Google Scholar 

  81. Jhaveri KD, Flombaum CD, Kroog G, Glezerman IG. Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature. Nephron Clin Pract. 2011;117(4):c312–9.

    Article  CAS  PubMed  Google Scholar 

  82. Eisen TT, Sternberg CNC, Robert CC, Mulders PP, Pyle LL, Zbinden SS, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst. 2012;104(2):93–113.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgement

The authors thank Paras Shah, MD, for assisting with the development of Table 9.2.

Author information

Authors and Affiliations

  1. Smith Institute of Urology, North Shore University Hospital and Long Island Jewish Medical Center, Hofstra North Shore-LIJ School of Medicine, 450 Lakeville Road, Suite M41, 11042, New Hyde Park, NY, USA

    Simpa S. Salami M.D., M.P.H.

  2. Smith Institute for Urology, North Shore University Hospital and Long Island Jewish Medical Center, Hofstra North Shore-LIJ School of Medicine, 450 Lakeville Road, Suite M41, 11042, Lake Success, NY, USA

    Manish A. Vira MD

  3. Hematology-Oncology, Monter Cancer Center, North Shore University Hospital and Long Island Jewish Medical Center, Hofstra North Shore-LIJ School of Medicine, 450 Lakeville Road, 11042, Lake Success, NY, USA

    Thomas P. Bradley MD

Authors
  1. Simpa S. Salami M.D., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manish A. Vira MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas P. Bradley MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simpa S. Salami M.D., M.P.H. .

Editor information

Editors and Affiliations

  1. Department of Medicine, Division of Kidney Diseases and Hypertension, North Shore University Hospital and Long Island Jewish Medical Center, Hofstra North Shore LIJ School of Medicine, Great Neck, New York, USA

    Kenar D. Jhaveri

  2. Nephrology Section, General Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

    Abdulla K. Salahudeen

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Salami, S., Vira, M., Bradley, T. (2015). Surgical and Medical Options in the Management of Renal Cell Carcinoma. In: Jhaveri, K., Salahudeen, A. (eds) Onconephrology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2659-6_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-2659-6_9

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-2658-9

  • Online ISBN: 978-1-4939-2659-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation